

Author Index

- Al-Nakib, W., see Higgins, P.G., 141
 Alaghamandan, H.A., see Smee, D.F., 253
 Alaghamandan, H.A., see Smee, D.F., 263
 Anderson, K.P., see Fennie, E.H., 27
 Atchison, R.W., see Li, X.Q., 179
- Baba, M., see Ito, M., 289
 Babiuk, L.A., see Campos, M., 71
 Barnard, D.K., see Sidwell, R.W., 193
 Barnett, B.B., see Burns, III, N.J., 89
 Barrow, G.I., see Higgins, P.G., 141
 Bernstein, D.I., Loo, L.S. and Kohl, S.
 Antibody to cloned HSV glycoproteins B and
 D plus adult human leukocytes protect neonatal
 mice from lethal HSV infection, 279
 Bernstein, D.I., see Harrison, C.J., 209
 Bernstein, D.I., see Myers, M.G., 83
 Bielefeldt Ohmann, H., see Campos, M., 71
 Bonnez, W., see Reichman, R.C., 41
 Burns, III, N.J., Barnett, B.B., Huffman, J.H.,
 Dawson, M.I., Sidwell, R.W., De Clercq, E.
 and Kende M.
 A newly developed immunofluorescent assay for
 determining the Pichinde virus-inhibitory ef-
 fects of selected nucleoside analogues, 89
- Campos, M., Bielefeldt Ohmann, H., Hughes, G.,
 Babiuk, L.A. and Lawman, M.J.P.
 Studies on the in vitro biological activities of
 recombinant bovine tumor necrosis factor
 (rBoTNF) alpha. I. Synergistic antiviral effi-
 cacy of rBoTNF alpha, recombinant bovine in-
 terferon gamma (rBoIFN gamma) and their
 combination, 71
 Chang, R.S., see Ngan, F., 107
 Chou, T.-C., see Kong, X.-B., 153
 Conti, C., Orsi, N. and Stein, M.L.
 Effect of isoflavans and isoflavones on rhinovi-
 rus 1B and its replication in HeLa cells, 117
 Coppenhaver, D.H., see Hughes, T.K., 1
 Cottagnoud, P., Neftel, K.A., Hany, M. and
 Zinkernagel, R.M.
 Inhibition of HSV-1 and vaccinia virus replica-
 tion by cephalosporin derivatives, 59
- Dawson, M.I., see Burns, III, N.J., 89
 De Clercq, E., see Burns, III, N.J., 89
 De Clercq, E., see Ito, M., 289
 DeLong, D.C., see Higgins, P.G., 141
- Fanucchi, M.P., see Kong, X.-B., 153
 Farrar, G.H., see Taylor, D.L., 11
- Feldman, A., see Terry, B.J., 235
 Fellows, L.E., see Taylor, D.L., 11
 Fennie, E.H., Lie, Y.S., Low, M.-A.L., Gri-
 bling, P. and Anderson, K.P.
 Reduced mortality in murine cytomegalovirus
 infected mice following prophylactic murine in-
 terferon- γ treatment, 27
 Field, A.K., see Terry, B.J., 235
 Fohlman, J., see Ilbäck, N.-G., 129
 Fox, J.J., see Kong, X.-B., 153
 Frank, K.B., see Smee, D.F., 263
 Friman, G., see Ilbäck, N.-G., 129
- Gall, S.A., see Reichman, R.C., 41
 Gorelik, E., see Li, X.Q., 179
 Gribling, P., see Fennie, E.H., 27
- Haffey, M.L., see Terry, B.J., 235
 Hagen, M., see Terry, B.J., 235
 Hany, M., see Cottagnoud, P., 59
 Harrison, C.J., Jeniski, L., Voychehovski, T. and
 Bernstein, D.I.
 Modification of immunological responses and
 clinical disease during topical R-837 treatment
 of genital HSV-2 infection, 209
 Harrison, C.J., see Myers, M.G., 83
 Hasegawa, A., see Ikeda, S., 167
 Hayden, F.G., Innes, Jr., D.J., Mills, S.E. and
 Levine, P.A.
 Intranasal tolerance and histopathologic ef-
 fects of a novel synthetic interferon, rIFN-
 α Con1, 225
 Helbig, B., see Wutzler, P., 99
 Higgins, P.G., Barrow, G.I., Al-Nakib, W., Tyr-
 rell, D.A.J., DeLong, D.C. and Lenox-Smith,
 I.
 Failure to demonstrate synergy between inter-
 feron- α and a synthetic antiviral, enviroxime,
 in rhinovirus infection in volunteers, 141
 Hirabayashi, K., see Ito, M., 289
 Ho, M., see Li, X.Q., 179
 Homma, J.Y., see Ideka, S., 167
 Huffman, J.H., see Burns, III, N.J., 89
 Huffman, J.H., see Sidwell, R.W., 193
 Hughes, G., see Campos, M., 71
 Hughes, T.K., Kaspar, T.A. and Coppenhaver,
 D.H.
 Synergy of antiviral actions of TNF and IFN- γ :
 evidence for a major role of TNF-induced IFN-
 β , 1

- Ikeda, S., Kumazawa, Y., Nishimura, C., Nakatsuka, M., Homma, J.Y., Kiso, M. and Hasagawa, A.
Enhancement of nonspecific resistance to viral infection by chemically synthesized lipid A-subunit analogs with different backbone structures and acyl groups, 167
- Ikeda, S., Sai, K., Nishimura, C. and Yamamoto, A.
Antiherpes activity of the immunomodulator OK-432, a streptococcal preparation, in immunosuppressed mice (Short Communication), 299
- Ilbäck, N.-G., Fohlman, J. and Friman, G.
The anti-inflammatory effect of LS 2616 and poly I:C in coxsackievirus B3 induced murine myocarditis, 129
- Innes, Jr., D.J., see Hayden, F.G., 225
- Ito, M., Sato, A., Hirabayashi, K., Tanabe, F., S., Baba, M., De Clercq, E., Nakashima, H. and Yamamoto, N.
Mechanism of inhibitory effect of glycyrrhizin on replication of hyman immunodeficiency virus (HIV), 289
- Jeffries, D.J., see Taylor, D.L., 11
- Jenski, L., see Harrison, C.J., 209
- Kaspar, T.A., see Hughes, T.K., 1
- Kende, M., see Burns, III, N.J., 89
- Kini, G.D., see Smee, D.F., 253
- Kiso, M., see Ikeda, S., 167
- Kohl, S., see Bernstein, D.I., 279
- Kong, X.-B., Scheck, A.C., Price, R.W., Vidal, P.M., Fanucchi, M.P., Watanabe, K.A., Fox, J.J. and Chou, T.-C.
Incorporation and metabolism of 2'-fluoro-5-substituted arabinosyl pyrimidines and their selective inhibition of viral DNA synthesis in herpes simplex virus type 1 (HSV-1)-infected and mock-infected Vero cells, 153
- Kucera, P., see Reichman, R.C., 41
- Kumazawa, Y., see Ikeda, S., 167
- Lawman, M.J.P., see Campos, M., 71
- Lenox-Smith, I., see Higgins, P.G., 141
- Levine, P.A., see Hayden, F.G., 225
- Li, X.Q., Gorelik, E., Atchison, R.W., Ovejera, A. and Ho, M.
A new in vivo anti-viral assay using microencapsulated infected cell cultures, 179
- Lie, Y.S., see Fennie, E.H., 27
- Loo, L.S., see Bernstein, D.I., 279
- Low, M.-A.L., see Fennie, E.H., 27
- Mazina, K.E., see Terry, B.J., 235
- McKernan, P.A., see Smee, D.F., 263
- Meerbach, A., see Wutzler, P., 99
- Micha, J.P., see Reichman, R.C., 41
- Mills, S.E., see Hayden, F.G., 225
- Mobberley, M.A., see Taylor, D.L., 11
- Mounts, P., see Reichman, R.C., 41
- Meyers, M.G., Bernstein, D.I., Harrison, C.J. and Stanberry, L.R.
Herpes simplex virus glycoprotein treatment of recurrent genital herpes reduces cervicovaginal virus shedding in guinea pigs, 83
- Nakashima, H., see Ito, M., 289
- Nakatsuka, N., see Ikeda, S., 167
- Nash, R.J., see Taylor, D.L., 11
- Neftel, K.A., see Cottagnoud, P., 59
- Ngan, F., Chang, R.S., Tabbal, H.D. and Smith, K.M.
Isolation, purification and partial characterization of an active anti-HIV compound from the Chinese medicinal herb *Viola yedoensis*, 107
- Nishimura, C., see Ikeda, S., 167
- Nishimura, C., see Ikeda, S., 299
- Orsi, N., see Conti, C., 117
- Ovejera, A., see Li, X.Q., 179
- Pifat, D.Y., see Sidwell, R.W., 193
- Pradel, W., see Wutzler, P., 99
- Price, R.W., see Kong, X.-B., 153
- Ramasamy, K., see Smee, D.F., 263
- Reichman, R.C., Micha, J.P., Weck, P.K., Bonnez, W., Wold, D., Whisnant, J.K., Mounts, P., Trofatter, K.D., Kucera, P. and Gall, S.A.
Interferon alpha-n1 (wellferon0 for refractory genital warts: efficacy and tolerance of low dose systemic therapy, 41
- Revankar, G.R., see Smee, D.F., 263
- Robins, R.K., see Smee, D.F., 253
- Robins, R.K., see Smee, D.F., 263
- Ryder, T.A., see Taylor, D.L., 11
- Sai, K., see Ikeda, S., 299
- Sato, A., see Ito, M., 289
- Scheck, A.C., see Kong, X.-B., 153
- Shigeta, S., see Ito, M., 289
- Sidwell, R.W., Huffman, J.H., Barnard, D.L. and Pifat, D.Y.
Effects of ribamidine, a 3-carboxamidine derivative of ribavirin, on experimentally induced Phlebovirus infections, 193
- Sidwell, R.W., see Burns, III, N.J., 89

- Slusarchyk, W.A., see Terry, B.J., 235
- Smee, D.F., Alaghamandan, H.A., Kini, G.D. and Robins, R.K.
Antiviral activity and mode of action of ribavirin 5'-sulfamate against Semliki Forest virus, 253
- Smee, D.F., McKernan, P.A., Alaghamandan, H.A., Frank, K.B., Ramasamy, K., Revankar, G.R. and Robins, R.K.
Antiviral activities of 2'-deoxyribofuranosyl and arabinofuranosyl analogs of sangivamycin against retro- and DNA viruses, 263
- Smith, K.M., see Ngan, F., 107
- Stanberry, L.R., see Myers, M.G., 83
- Stein, M.L., see Conti, C., 117
- Tabba, H.D., see Ngan, F., 107
- Tanabe, F., see Ito, M., 189
- Taylor, D.L., Fellows, L.E., Farrar, G.H., Nash, R.J., Taylor-Robinson, D., Mobberley, M.A., Ryder, T.A., Jeffries, D.J. and Tyms, A.S.
Loss of cytomegalovirus infectivity after treatment with castanospermine or related plant alkaloids correlates with aberrant glycoprotein synthesis, 11
- Taylor-Robinson, D., see Taylor, D.L., 11
- Terry, B.J., Mazina, K.E., Tuomari, A.V., Haffey, M.L., Hagen, M., Feldman, A., Slusarchyk, W.A., Young, M.G., Zahler, R. and Field, A.K.
Broad-spectrum antiviral activity of the acyclic guanosine phosphate (R,S)-HPMPG, 235
- Trofatter, K.F., see Reichman, R.C., 41
- Tuomari, A.V., see Terry, B.J., 235
- Tyms, A.S., see Taylor, D.L., 11
- Tyrrell, D.A.J., see Higgins, P.G., 141
- Ulbricht, A., see Wutzler, P., 99
- Vidal, P.M., see Kong, X.-B., 153
- Voychehovski, T., see Harrison, C.J., 209
- Watanabe, K.A., see Kong, X.-B., 153
- Weck, P.K., see Reichman, R.C., 41
- Whisnant, J.K., see Reichman, R.C., 41
- Wold, D., see Reichman, R.C., 41
- Wutzler, P., Helbig, B., Ulbricht, A., Meerbach, A. and Pradel, W.
Therapeutic effect of pyrophosphate analogues on cutaneous herpes simplex virus type 1 infection in guinea pigs, 99
- Yamamoto, A., see Ikeda, S., 299
- Yamamoto, N., see Ito, M., 289
- Young, M.G., see Terry, B.J., 235
- Zahlerr, R., see Terry, B.J., 235
- Zinkernagel, R.M., see Cottagnoud, P., 59